ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ARTLW Artelo Biosciences Inc

0.0102
0.0002 (2.00%)
May 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,653
Bid Price 0.0001
Ask Price 2,147.48
News -
Company Name Stock Ticker Symbol Market Type
Artelo Biosciences Inc ARTLW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
0.0002 2.00% 0.0102 16:00:01
Open Price Low Price High Price Close Price Prev Close
0.01 0.01 0.013 0.0102 0.01
Trades Volume VWAP Dollar Volume Avg Volume
13 3,653  0.0103002  38 -
Last Trade Time Type Quantity Stock Price Currency
16:00:00 100  0.013 USD

Artelo Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.59M 3.19M - 0 -9.29M -2.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Artelo Biosciences

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARTLW Message Board. Create One! See More Posts on ARTLW Message Board See More Message Board Posts

ARTLW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Your Recent History

Delayed Upgrade Clock